CKPT
Price:
$3.54
Market Cap:
$170.39M
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a tre...[Read more]
Industry
Biotechnology
IPO Date
2016-12-19
Stock Exchange
NASDAQ
Ticker
CKPT
According to Checkpoint Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 165.69M. This represents a change of 141.24% compared to the average of 68.68M of the last 4 quarters.
The mean historical Enterprise Value of Checkpoint Therapeutics, Inc. over the last ten years is 78.29M. The current 165.69M Enterprise Value has changed 21.06% with respect to the historical average. Over the past ten years (40 quarters), CKPT's Enterprise Value was at its highest in in the March 2017 quarter at 243.44M. The Enterprise Value was at its lowest in in the March 2015 quarter at 0.
Average
78.29M
Median
68.54M
Minimum
29.97M
Maximum
181.72M
Discovering the peaks and valleys of Checkpoint Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 209.36%
Maximum Annual Enterprise Value = 181.72M
Minimum Annual Increase = -81.80%
Minimum Annual Enterprise Value = 29.97M
Year | Enterprise Value | Change |
---|---|---|
2023 | 37.99M | 14.84% |
2022 | 33.08M | -81.80% |
2021 | 181.72M | 69.55% |
2020 | 107.18M | 209.36% |
2019 | 34.65M | 15.59% |
2018 | 29.97M | -56.27% |
2017 | 68.54M | -50.07% |
2016 | 137.27M | 85.04% |
The current Enterprise Value of Checkpoint Therapeutics, Inc. (CKPT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
84.27M
5-year avg
78.92M
10-year avg
78.29M
Checkpoint Therapeutics, Inc.’s Enterprise Value is greater than Mustang Bio, Inc. (5.46M), greater than Reviva Pharmaceuticals Holdings, Inc. (70.91M), greater than Fortress Biotech, Inc. (60.71M), less than Kodiak Sciences Inc. (362.34M), greater than Fortress Biotech, Inc. (60.71M), greater than Avenue Therapeutics, Inc. (1.10M), greater than Pieris Pharmaceuticals, Inc. (-1407736.00), greater than Aileron Therapeutics, Inc. (22.86M), greater than CytomX Therapeutics, Inc. (55.32M), less than Instil Bio, Inc. (220.42M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Spero Therapeutics, Inc. (-21358605.00), greater than Assembly Biosciences, Inc. (67.83M), greater than Achilles Therapeutics plc (-42104641.00), greater than Cue Biopharma, Inc. (42.98M), greater than Medicenna Therapeutics Corp. (113.60M), less than XOMA Corporation (290.55M), greater than ZIVO Bioscience, Inc. (78.24M), greater than Lumos Pharma, Inc. (24.19M),
Company | Enterprise Value | Market cap |
---|---|---|
5.46M | $8.00M | |
70.91M | $76.39M | |
60.71M | $47.09M | |
362.34M | $486.77M | |
60.71M | $48.03M | |
1.10M | $3.70M | |
-1407736.00 | $17.96M | |
22.86M | $40.52M | |
55.32M | $85.30M | |
220.42M | $141.74M | |
-6333315.00 | $8.20M | |
-21358605.00 | $50.31M | |
67.83M | $94.84M | |
-42104641.00 | $40.33M | |
42.98M | $65.88M | |
113.60M | $0 | |
290.55M | $301.17M | |
78.24M | $78.37M | |
24.19M | $37.54M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Checkpoint Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Checkpoint Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Checkpoint Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Checkpoint Therapeutics, Inc. (CKPT)?
What is the 3-year average Enterprise Value for Checkpoint Therapeutics, Inc. (CKPT)?
What is the 5-year average Enterprise Value for Checkpoint Therapeutics, Inc. (CKPT)?
How does the current Enterprise Value for Checkpoint Therapeutics, Inc. (CKPT) compare to its historical average?